Supplementary Table 9 ǀ Aneuploidy and prognosis in patients with bladder carcinoma
Study (year of
publication)
Method of ploidy
measurement
Cancer
type
Number of
patients
Tumour
stage
Diploid
(%)
Follow-up
duration
End
point
P value
Bollmann et al.
(2009)S96
ICM- suspension
UCC
22
pTa, pT1
54%
34 mo
RFS
NS
Cai et al.
(2006)S97
ICM-imprint
TCB
29
pTa–pT4
45%
10 yrs
RFS,
Yamamoto et
al. (2006)S98
Deliveliotis et
al. (2005)S99
Ali-El-Dein et
al. (2003)S100
LSC
UCC
100
pTa–pT4
53%
42 mo
PFS
RFS in superficial TCB :
P = 0.049 (U)
RFS in pT1–pT4 TCB: NS
RFS in pTa–pT4 (U):
P = 0.0006
P = 0.033 (U)
FCM
TCB
66
T1–T4
39%
68 mo
MS
FCM-F
TCB
pTa: 38
pT1: 339
pTa–pT1
83%
58 mo
RFS,
PFS
P <0.001 (U)
P = 0.006; HR 72 (M)
RFS: P = 0.002; HR 2.04 (M)
PFS: P = 0.03; HR 2.06 (M)
Bol et al.
(2003)S101
Loughman et
al. (2003)S102
ICM- suspension
UCC
Ta–T1
TCB
3 yrs
RFS,
PFS
TTR
PFS in Ta–T1 group:
P = 0.0002; HR 10.2 (U)
G2: P = 0.003 (U)
Lavezzi et al.
(2001)S103
ICM-section
TCB
177
T1
Ta: 70%
T1: 29%
G1:
100%
G2: 61%
G3: 0%
56%
48 mo
ICM-suspension
Ta: 132
T1: 39
119
5 yrs
OS
NS (U)
G1–G3
Abbreviations: FCM, flow cytometry; FCM-F, flow cytometry using fresh or frozen material; G, grade;
HR, hazard ratio; ICM, image cytometry; LSC, laser scanning cytometry; M, on multivariate analysis;
M+, distant metastasis; M0, no metastasis; mo, months; MS, median survival; NA, not applicable; NS,
not significant; OS, overall survival; PFS, progression-free survival; RFS, recurrence-free survival; TCB,
transitional cell carcinoma of bladder; TTR, time to recurrence; U, on univariate analysis; UCC,
urothelial cell carcinoma; yrs, years.
S96.
S97.
S98.
S99.
S100.
S101.
S102.
S103.
Bollmann, D. et al. Quantitative molecular grading of bladder tumours: a tool for objective
assessment of the biological potential of urothelial neoplasias. Oncol.Rep. 21, 39-47 (2009).
Cai, T. et al. Prognostic value of static cytometry in transitional cell carcinoma of the bladder:
recurrence rate and survival in a group of patients at 10 years follow-up. Oncol.Rep. 15, 213219 (2006).
Yamamoto, Y. et al. Biological characteristics in bladder cancer depend on the type of genetic
instability. Clin. Cancer Res. 12, 2752-2758 (2006).
Deliveliotis, C. et al. DNA ploidy as a prognostic factor in muscle invasive transitional cell
carcinoma of the bladder. Urol.Res. 33, 39-43 (2005).
Ali-El-Dein, B. et al. Superficial bladder tumours: analysis of prognostic factors and
construction of a predictive index. BJU Int. 92, 393-399 (2003).
Bol, M.G. et al. Proliferation markers and DNA content analysis in urinary bladder TaT1
urothelial cell carcinomas: identification of subgroups with low and high stage progression
risks. J. Clin. Pathol. 56, 447-52 (2003).
Loughman, N.T., Lin, B.P., Dent, O.F. & Newland, R.C. DNA ploidy of bladder cancer using
bladder biopsy supernate specimens. Anal. Quant. Cytol. Histol. 25, 146-158 (2003).
Lavezzi, A.M. et al. The role of different biomarkers (DNA, PCNA, apoptosis and karyotype) in
prognostic evaluation of superficial transitional cell bladder carcinoma. Anticancer Res. 21,
1279-1284 (2001).